Iovance Biotherapeutics Inc
(IOVA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 31,106 | 715 | 482 | 469 | 238 |
| Cost of Goods | 31,368 | 7,261 | 4,365 | 4,340 | 2,050 |
| Gross Profit | -262 | -6,546 | -3,883 | -3,871 | -1,812 |
| Operating Expenses | 102,020 | 111,437 | 117,738 | 114,830 | 108,324 |
| Operating Income | -101,914 | -117,722 | -121,256 | -118,361 | -110,086 |
| Other Income | 3,355 | 3,338 | 3,118 | 3,358 | 3,081 |
| Pre-tax Income | -98,559 | -114,384 | -118,138 | -115,003 | -107,005 |
| Income Tax | -1,458 | -1,408 | -1,759 | -1,243 | -477 |
| Net Income Continuous | -97,101 | -112,976 | -116,379 | -113,760 | -106,528 |
| Net Income | $-97,101 | $-112,976 | $-116,379 | $-113,760 | $-106,528 |
| EPS Basic Total Ops | -0.34 | -0.42 | -0.46 | -0.46 | -0.47 |
| EPS Basic Continuous Ops | -0.34 | -0.42 | -0.45 | -0.46 | -0.47 |
| EPS Diluted Total Ops | -0.34 | -0.42 | -0.46 | -0.46 | -0.47 |
| EPS Diluted Continuous Ops | -0.34 | -0.42 | -0.45 | -0.46 | -0.47 |
| EPS Diluted Before Non-Recurring Items | -0.34 | -0.42 | -0.45 | N/A | N/A |
| EBITDA(a) | $-93,549 | $-110,150 | $-113,269 | $-110,364 | $-101,267 |